Show simple item record

dc.contributor.authorGreystoke, Alastair
dc.contributor.authorMullamitha, Saifee A
dc.date.accessioned2012-12-05T16:59:25Z
dc.date.available2012-12-05T16:59:25Z
dc.date.issued2012
dc.identifier.citationHow many diseases are colorectal cancer? 2012, 2012:564741 Gastroenterol Res Practen_GB
dc.identifier.issn1687-630X
dc.identifier.pmid22991509
dc.identifier.doi10.1155/2012/564741
dc.identifier.urihttp://hdl.handle.net/10541/254628
dc.description.abstractThe development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called colorectal cancer. Differences in the aetiology and epidemiology of proximal and distal cancers are reflected in different clinical behaviour, histopathology, and molecular characteristics of these tumours. This may impact response both to standard cytotoxic therapies and mechanism-targeted agents. This disease heterogeneity leads to challenges in the design of clinical trials to assess novel therapies in the treatment of "colorectal cancer."
dc.language.isoenen
dc.rightsArchived with thanks to Gastroenterology research and practiceen_GB
dc.titleHow many diseases are colorectal cancer?en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie NHS Foundation Trust, Manchester M20 4BX, UK ; School of Cancer and Imaging Sciences, University of Manchester, Manchester M13 9PL, UK.en_GB
dc.identifier.journalGastroenterology Research and Practiceen_GB
html.description.abstractThe development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called colorectal cancer. Differences in the aetiology and epidemiology of proximal and distal cancers are reflected in different clinical behaviour, histopathology, and molecular characteristics of these tumours. This may impact response both to standard cytotoxic therapies and mechanism-targeted agents. This disease heterogeneity leads to challenges in the design of clinical trials to assess novel therapies in the treatment of "colorectal cancer."


This item appears in the following Collection(s)

Show simple item record